ARCH Venture Partners
About ARCH Venture Partners
ARCH is an early-stage venture firm that focuses on life science discoveries to prevent, detect, and cure disease.
Investment focus
Stages
Sectors
Portfolio (26 in our database)
Generate BiomedicinesGenerate Biomedicines is a biotechnological company focusing on creating breakthrough medicines.Series B · $420M raisedAledadeAledade is a primary care physician platform that provides everything doctors need to create and run an accountable care organization.Series E · $418M raisedVividion TherapeuticsVividion is a developer of a novel drug discovery platform designed to offer transformative treatments to patients with serious illnesses.Acquired · $372M raisedSonoma BioTherapeuticsSonoma BioTherapeutics develops adoptive Treg therapies cell for autoimmune.Series B · $335M raisedPrime MedicinePrime Medicine operates as a biotechnology company that delivers the promise of gene editing using Prime Editing.Series B · $315M raisedLifeMine TherapeuticsLifeMine Therapeutics combines genomics with AI and synthetic biology to discover and develop a pipeline of novel medicines.Series C · $295M raisedDewpoint TherapeuticsDewpoint Therapeutics is a biotech company developing a drug platform that targets biomolecular condensates.Series C · $287M raisedEGenesisEGenesis focuses on leveraging genome editing technology to deliver safe and effective human transplantable cells, tissues, and organs.Series C · $265M raisedAgBiomeAgBiome discovers and develops innovative biological and trait products for crop protection.Series D · $253M raisedNutcracker TherapeuticsNutcracker Therapeutics is a biotech company that develops mRNA therapeutics.Series C · $241M raisedEncoded TherapeuticsEncoded Therapeutics is a Harnessing the regulatory genome to create next-generation molecular therapies.Series D · $239M raisedNanosysNanosys specializes in the development of quantum dot technology for displays.Series I · $186M raisedBe BiopharmaBe Biopharma is developing B ceaBe Biopharma is a biotech research company that develops a class of B cells as medicines.lls as medicines.Series B · $182M raisedSemma TherapeuticsSemma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.Acquired · $163M raisedMindstrongMindstrong is committed to reshaping mental health through improvements in data measurement, data science, and virtual care models.Series C · $160M raisedHiberCellHiberCell is a biotechnology company developing treatments to prevent cancer relapse and metastasis.Series B · $158M raisedKSQ TherapeuticsKSQ Therapeutics is using CRISPR technology within a powerful drug discovery engine to enable high-confidence drug development.Series C · $156M raisedLocanabioLocana develops RNA-targeting gene therapies for patients with severe neurodegenerative, neuromuscular, and retinal diseases.Series B · $156M raisedBoundless BioBoundless Bio is a precision oncology company developing therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers.Series B · $151M raisedRemix TherapeuticsRemix Therapeutics is a biotechnology company.Series B · $151M raisedVizgenVizgen is a biotech company that develops solutions for next-generation spatially resolved, single-cell transcriptomics.Series C · $136M raisedROME TherapeuticsROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome.Series B · $127M raisedUltivueUltivue is a biotechnology company that specializes in tissue imaging, diagnostics, and multiplexing.Series D · $107M raisedInterline TherapeuticsInterline Therapeutics is a drug discovery platform that enables the company to map and correct dysfunctional protein communities.Series A · $92M raisedEncodiaEncodia is a biotech company that develops the next generation of protein analysis tools.Series C · $75M raisedAiraAira provides tech-enabled services for the 300 million visually impaired people around the globe.Acquired · $36M raised